Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00865215 · ClinicalTrials.gov registry record · Phase 1
A Relative Bioavailability Study of Propranolol Hydrochloride 160 mg Tablets Under Fasting Conditions
A Phase 1 study, sponsored by Actavis.
- Completed
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
NCT00865215 is a Phase 1 study that has completed, run by Actavis. The registered enrollment target is 60 participants.
The verdict
NCT00865215, a Phase 1 study, has completed, sponsored by Actavis.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
Study Summary
The purpose of this study is TO compare the relative bioavailability of Propranolol Hydrochloride Extended Release Capsules 160 mg (Actavis) with that of INDERAL® LA 160 mg Capsules (Wyeth Pharmaceuticals) following a single oral dose (1 x 160 mg) in healthy adult volunteers under fasting conditions.
Interventions
- DRUG Propranolol Hydrochloride Extended Release Capsules 160 mg
- DRUG INDERAL® LA 160 mg Capsules, single dose
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2005-04 |
| Est. Completion | 2005-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00865215
The ClinicalTrials.gov registry entry for NCT00865215 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Actavis, which has 79 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Propranolol Hydrochloride Extended Release Capsules 160 mg is the first listed.
NCT00865215 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00865215 about?
NCT00865215 is a clinical study titled "A Relative Bioavailability Study of Propranolol Hydrochloride 160 mg Tablets Under Fasting Conditions". The purpose of this study is TO compare the relative bioavailability of Propranolol Hydrochloride Extended Release Capsules 160 mg (Actavis) with that of INDERAL® LA 160 mg Capsules (Wyeth Pharmaceuticals) following a single oral dose (1 x 160 mg) in healthy adult volunteers under fasting conditions...
What is the current status of trial NCT00865215?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2005-04. Estimated completion is 2005-04.
What interventions are being tested in trial NCT00865215?
The interventions under investigation include: Propranolol Hydrochloride Extended Release Capsules 160 mg (DRUG), INDERAL® LA 160 mg Capsules, single dose (DRUG).
Who is sponsoring clinical trial NCT00865215?
This trial is sponsored by Actavis, which has 79 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.